Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 285,878 shares of the specialty pharmaceutical company’s stock after selling 6,530 shares during the quarter. California Public Employees Retirement System owned about 0.47% of Jazz Pharmaceuticals worth $35,206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $25,000. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $28,000. Allianz SE purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $29,000. Jones Financial Companies Lllp boosted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares during the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the transaction, the chief executive officer now owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,236 shares of company stock valued at $3,837,680. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $126.44 on Thursday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The business has a 50 day moving average price of $132.54 and a two-hundred day moving average price of $122.92. The firm has a market cap of $7.68 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Analysts Set New Price Targets

A number of research analysts recently weighed in on JAZZ shares. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Barclays reissued an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.